// App-Quantinova.ai

1658 : M3814, a novel investigational DNA-PK inhibitor: enhancing the effect of fractionated radiotherapy leading to complete regression of tumors in mice

Researchers

Presenter

  • Frank T. Zenke

Principal Investigators

  • Astrid Zimmermann

  • Christian Sirrenberg

  • Heike Dahmen

  • Lubo Vassilev

  • Ulrich Pehl

  • Thomas Fuchss

  • Andree Blaukat

Medical Centers

  • Merck KGaA, Darmstadt, Germany

  • EMD Serono, Inc, Billerica, MA

Locations

  • United States

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • Protein Kinase, DNA-Activated, Catalytic Subunit

  • Ku70

  • X-Ray Repair Cross Complementing 5

Drug/Treatment

  • M3814

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved